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 The invention of rapid-acting insulin analogs, such as aspart, was a great step 
forward in achieving optimal control of blood glucose in patients with type 1 diabetes. 
Aspart’s action resembles the physiologic endogenous post-meal insulin action; however, 
the slow rate of absorption through subcutaneous tissue leads to a delay in the time to 
peak levels and action of pre-meal insulin injection and suboptimal control of 
postprandial blood glucose excursions. We propose that massaging the site of aspart 
injection will significantly accelerate insulin action and mitigate postprandial blood 
glycemic excursions. The study will investigate the effect of injection site massage on the 
pharmacokinetics and pharmacodynamics of subcutaneously administered aspart in 
overweight and obese adolescents with type 1 diabetes who are at high-risk for impaired 
insulin action. Massage will offer a cost effective solution to the undesired postprandial 
glycemic excursions that directly and indirectly contribute to mortality and morbidity 
associated with diabetes.
 1 
CHAPTER I: INTRODUCTION 
Background 
 Type 1 diabetes mellitus (T1DM) is a common metabolic disorder that is a result 
of multifactorial interactions including genetic, environmental and immunologic factors. 
It is characterized by an absolute insulin deficiency due to an autoimmune destruction of 
beta cells of the pancreas. It accounts for 5-10% of the world’s diagnosed diabetes, and 
its incidence has been gradually increasing 2-5% annually.1-3 There are approximately 
15,600 children, inducing adolescents, diagnosed with T1DM every year.4 The majority 
of these children with T1DM are not achieving target blood sugar levels and overall 
glycemic control with only 32% reaching the age specific target hemoglobin A1c 
(HbA1c) set by the American Diabetes Association (ADA).5,6 This challenge of 
achieving an optimal glycemic control is particularly emphasized in the adolescent 
population as demonstrated by data from the T1DM Exchange Clinic Registry. Out of all 
the participants in the registry, children between the ages of 13 and 26 years old had the 
highest HbA1c at 8.7%.7 Additionally, data collected from the same cohort showed that 
only 21% of adolescent participants (ages 13-20 years old) met the HbA1c target of < 
7.5% set by the ADA and International Society for Pediatric and Adolescent Diabetes 
(ISPAD).5,6,8 
 A few physiological and behavioral factors suggest why T1DM adolescents have 
higher mean hemoglobin A1c (HbA1c) values compared to the rest of the pediatric 
population and adult counterparts.9  The main physiologic factor that contributes to poor 
glycemic control in adolescents is the significantly reduced insulin sensitivity secondary 
to pubertal changes, which in turn impairs insulin-stimulated glucose metabolism.10-12 In 
healthy (non-diabetic) individuals, when a meal intake is initiated, the pancreas 
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immediately starts rapid production of insulin. Within 30-45 minutes, the insulin in the 
bloodstream reaches its maximal concentration.13 By binding to receptors in target 
peripheral tissues and activating the trafficking of glucose transporters onto cell surfaces, 
this insulin facilitates the effective uptake of postprandial blood glucose (PPG), which 
reaches its peak level at ~60-75 minutes.3,14,15 The hepatic production of glucose is also 
reduced by direct and indirect insulin action. This physiologic mechanism is impaired in 
patients with T1DM resulting in an ineffective metabolism of ingested mixed meals.16 In 
the pubertal population, the increased insulin resistance (IR) leads to an increased and 
long-lasting PPG levels compared to healthy individuals.  
 These abnormally high and prolonged glucose elevations seen in the T1DM 
adolescent population are referred to as postprandial blood glucose excursions (PPGEs), 
or postprandial hyperglycemia (PPH). According to the ADA, PPGEs are glucose values 
defined as the change from baseline blood glucose levels or increments above the pre-
meal blood glucose levels.14 These PPGEs in the adolescent population are of a clinical 
significance because they are major contributors to overall glycemic control as well as 
independent risk factors of vascular complications associated with T1DM17-20.  
 Besides the distinct physiological factor in adolescents that contributes to their 
poor glycemic control, this pubertal age group is also considered fragile in terms of some 
behavioral factors. The T1DM Exchange clinic registry data reports a poor adherence of 
the pediatric population to the recommended regular continuous glucose monitoring in 
order to adjust pre-meal insulin therapy accordingly7. In addition, as T1DM children 
reach their teenage years, there is a struggle to find a balance between their need to gain 
independence from parents and the vitality of continual supervision and assistance in 
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regards to insulin therapy decision-making.21 This challenge becomes even more 
pertinent considering the reported low adherence of patients with diabetes to the 
recommended injection of rapid-acting insulin analogs (RAIAs) 15-30 minutes pre-meal 
for optimal control of PPGEs.22,23  
 RAIA therapy provides the most effective and safe insulin therapy that closely 
resembles the endogenous secretion of insulin.24 Relative to the previously used human 
insulin, these RAIAs have a much faster onset and shorter duration of action. However, 
even with an improved pharmacokinetic (PK) and pharmacodynamic (PD) profile, 
RAIAs still have shortcomings that interfere with the goal of tight glycemic control in 
T1DM management. Per guidelines, RAIAs are subcutaneously (SC) injected before a 
meal in order to reproduce the instantaneous physiologic increase in insulin secretion that 
occurs after carbohydrate intake in those without diabetes. However, due to the slow rate 
of absorption through the SC tissue, there is a delay in the time to peak action of these 
analogs. It is known that SC injected analogs require up to 1hr to reach maximum 
concentration in the bloodstream and up to 90-120 min to reach a maximal glucose 
lowering effect16. This delay is associated with the incidence of PPH in children, with 
PPG excursions reaching over 300 mg/dl25 above the recommended PPG level of < 
180mg/dl.5  
 The contribution of overall glycemic control to the micro and macro-vascular 
complications seen over time in T1DM patients has long been understood.9,26-28 Over the 
past two decades, many prospective studies and epidemiological data have demonstrated 
the significant contribution of glycemic variability independent of long-term glycemic 
control to the development of these complications.18,19,29,30 Daily fasting glucose 
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fluctuations significantly contribute to acute and long-term glycemic variability. Contrary 
to previous belief, PPG spikes also contribute to vascular complications.17-20 Therefore, it 
is crucial to find ways such as an ultrafast-acting insulin to prevent postprandial 
hyperglycemic states by hastening the absorption of SC administered RAIAs and 
mimicking the function of pancreatic beta cells.31 This is especially important in the 
obese and overweight adolescent population, as they constitute a high-risk group within 
the pediatric population of T1DM.   
 According to the American Academy of Pediatrics and Center for Disease Control 
(CDC)’s sex and age-specific growth ranking charts, overweight and obesity in the 
pediatric population ages 2-19 years are defined as a BMI percentile that is ≥ 85% and < 
95% and ≥ 95% and < 99% respectively.32,33 Currently, 21% of pediatric patients newly 
diagnosed with T1DM are obese or overweight,34 and this has been significantly rising 
since the 1980s.35 Besides the aforementioned physiological and behavioral factors, this 
particular group of obese and overweight adolescents has an added obstacle in achieving 
optimal glycemic control. Primarily, the increase in fat mass observed in this group 
contributes to the already high IR of body tissue seen in adolescents.11 Secondly, the 
increased injection site SC fat is negatively correlated to the rate of absorption of SC 
injected RAIAs.36 Lastly, it is well known that this group is at a higher risk of developing 
cardiovascular diseases than the lean counterpart.37 All these factors place the adolescent 
population at the frontline to benefit from an intervention that will provide improved 
insulin absorption and action. 
 There are various approaches that have been investigated in an attempt to increase 
the rate of absorption and thus, action of SC injected insulin analogs. These include, the 
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manipulation of the insulin formulation, delivery method and injection site stimulations 
to increase blood flow. Results from many studies investigating such methods have been 
promising (discussed in detail in Chapter II).16,38-42 However, there is not yet one 
universally accepted practical solution to mitigate the PPGEs seen in T1DM patients.  
 Massage is one approach that was introduced in the 1980s with some promising 
preliminary results suggesting an improved SC insulin absorption and action in T1DM 
patients. There is only one massage study that was done in T1DM patients, and it was a 
poorly controlled 1983 trial. The study used local skin massage 15 minutes post-insulin 
administration in lean, well-controlled, insulin-dependent patients and showed a 
significantly higher insulin concentration and reduced serum glucose level 45 minutes 
after SC injection of a mixed regular and intermediate-acting insulin.38 The overall 
metabolic control of these patients as well as an additional 18 participants after 3-6 and 8-
12 months of therapy was also significantly improved from baseline. This study, even 
with many limitations, had illustrated the potential of a simple, yet practical solution to 
the unquestionable need for an ultrafast-acting insulin therapy. Thus, there is an obvious 
need for well-controlled trials to investigate the benefit of local skin massage specifically 
using RAIAs in T1DM patients.  
Statement of the Problem: 
 Rapid-acting insulin analog therapy has improved overall glycemic control in 
T1DM patients. Compared to regular human insulin these analogs have a faster and 
higher serum insulin peak and a much shorter duration of action. This has allowed for 
significantly reduced and shorter PPGEs as well as reduced incidence of 
hypoglycemia.24,43-46 RAIAs, however, are not fast-acting enough to overcome the 
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glycemic control challenges faced by the overweight and obese adolescent T1DM 
patients. There is an increasing prevalence of overweight and obesity at the time of 
T1DM diagnosis7,34,37. Overweight and obese adolescents face additional obstacles in 
diabetes treatment because of a higher insulin resistance associated with increased body 
mass11 and pubertal hormonal changes10,47 as well as a delayed absorption of insulin 
analogs due to increased SC fat.36 Therefore, this population will significantly benefit 
from an acceleration of insulin absorption and action to achieve good glycemic control by 
specifically targeting PPGEs.  
 The discontinued interest in massage as a potential solution to this obstacle was 
surprising to find in the literature considering the fact that massage, if proven efficacious, 
does not require many resources besides educating patients on how to apply a 
standardized massaging technique. Besides the risk of hypoglycemia suggested in studies 
that were not undertaken in T1DM patients,48,49 there are no reported adverse effects 
associated with the use of massage therapeutically. Additionally, local skin massage will 
not add cost to the already burdensome expenses of T1DM management, and this, as well 
as its non-invasive nature, makes it an interesting and practical solution to mitigate PPH.  
Goals and Objectives: 
 The goal of this study is to evaluate the effect of a standardized local skin 
massage at the site of SC aspart injection on insulin action in overweight and obese 
adolescents with T1DM at the Yale Pediatric Diabetes Clinic. Massage has the potential 
to accelerate SC administered insulin absorption and action to moderate the PPG levels 
that are elevated and prolonged in overweight and obese adolescents. Faster insulin 
action by massaging will reduce the PPGEs in this population leading to an improved 
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short-term glycemic variability as well as long-term glycemic control, which in turn 
might decrease the risk of developing micro and macrovascular complications associated 
with T1DM.  
 The objective of this proposed study is to gather preliminary data regarding 
differences in the onset, peak and duration of action of aspart by comparing mean values 
after treatment with SC abdominal (10cm from the umbilicus) aspart injection followed 
by a 3-minute standardized local skin massage with the control treatment, identical dose 
of SC aspart injection without massaging. These data will be collected using the gold 
standard insulin action test, the euglycemic clamp technique50 (refer to Chapter III). This 
study would also provide a pilot protocol that other studies can adopt and modify to 
establish an optimal standardized insulin infusion site massage protocol to accelerate 
insulin absorption and action.  
Hypothesis: 
 The primary hypothesis of this proposal is that overweight and obese type 1 
diabetes mellitus patients ages 12-18 years old, who massage the site of injection of the 
rapid-acting insulin analog, aspart, for 3 minutes after SC abdominal injection will have a 
statistically significant increase in the rate of insulin absorption and action. The measure 
of insulin absorption is defined as time to maximal serum insulin concentration (T-
INSmax) and insulin action is defined as time to maximal glucose infusion rate (T-
GIRmax) during an insulin action study. We expect that the mean time to peak serum 
insulin concentration between the two intervention groups will differ by at least 33 
minutes. This will be a clinically significant difference provided that it is longer than the 
 8 
~20 min delay of aspart in reaching maximal serum concentration as compared to the 
physiologic insulin peak time. 
 We also expect a difference in change in our secondary outcomes between the 
two study days where participants receive either SC aspart injection or a 3-min local skin 
massage post-SC aspart injection. The secondary pharmacokinetic outcomes will include, 
the peak insulin levels (C-INSmax) and the total area under the curve for change in 
insulin levels (AUCINS). The secondary pharmacodynamic outcomes will include the 
maximal glucose infusion rate (GIRmax) and the total area under the curve for the change 
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CHAPTER II: LITERATURE REVIEW 
Introduction: 
 This proposal is based on a literature review conducted between December 2013 
and May 2014. Databases used to gather information relevant to the proposal include 
Medline, PubMed, Embase and Cochrane Library. The search was restricted to articles 
published from 1973 to present. References from retrieved publications were also used to 
expand literature search. Only clinical trials in humans were included. Search terms or 
keywords used include, type 1 diabetes mellitus, obesity, puberty, massage, rapid-acting 
insulin analogs, insulin absorption, insulin resistance, postprandial glycemic excursion, 
microneedles, warming device and hyaluronidase. 
Review of Empiric Studies: 
Prevalence and Implications of Postprandial Hyperglycemia   
 Glycemic management in type 1 and 2 diabetes mellitus is based on the overall 
glycemic control as measured by glycated hemoglobin (HbA1c). This focus of 
management in T1DM patients is based on the outcomes of a prospective study, the 
Diabetes Control and Complications Trial (DCCT), which showed that HbA1c, a 
measure that reflects plasma glucose concentration over the preceding 2-3 months, is 
directly associated with the late-stage macrovascular and microvascular complications of 
T1DM (including retinopathy, nephropathy and neuropathy).1,2 Based on findings from 
the DCCT, the American Association of Diabetes to this day recommends a tight 
glycemic control in all non-pregnant adults with an HbA1c of < 7%.3 However, more 
recent studies indicate that HbA1c values are merely a fragment of the multiple risk 
factors of complications associated with T1DM. Acknowledging the immense role of the 
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DCCT in the improved management of diabetic patients, Hirsch and Brownlee in 2010 
illustrated that the contribution of HbA1c and duration of diabetes to the risk of 
development of retinopathy seen on this trial was overall very low at 11%.4 This 
commentary suggested that there are many other factors that must be contributing to the 
variation in risk for microvascular complications.  
 Various epidemiologic as well as experimental studies over the years have shown 
that overall long-term and short-term glycemic variability around a stable mean baseline 
HbA1c also plays a significant role in predicting microvascular and macrovascular 
complications in the diabetic population.5-14 This glycemic variability is associated with 
the vascular complications of diabetes both as an independent risk factor5,9,14-16 and 
indirectly by affecting the overall glycemic control (HbA1c).17,18  
 Glycemic variability was initially thought to be solely a result of the daily 
variations in fasting glucose levels. However, many studies have established the 
contribution of PPGEs to long-term and acute glucose fluctuations (glycemic 
variabilities) seen in patients with diabetes.7,9,11 Boland et al. first emphasized the 
prevalence and possible clinical implication of PPGEs in their study of continuous 
glucose monitoring system in a cohort of 56 children ages < 18. They demonstrated that 
PPG values were significantly elevated above the target value of < 180 mg/dl in ~90% of 
the children after a 3-day monitoring trial. Out of these, 50% were above 300 mg/dl 
despite having HbA1c values within the target range.8 This study suggested that even in 
those T1DM patients with a relatively optimal HbA1c and pre-meal glucose values, 
marked glycemic excursions post-meal are of a significant existence.  
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 Monnier et al. further asserted these findings in 2003 by comparing the relative 
contribution of fasting and postprandial plasma glucose excursions to the overall 
hyperglycemia of patients with type 2 diabetes mellitus (T2DM).17 They found that both 
were major contributors to the overall glycemic control of diabetes patients, but PPH had 
a significant contribution in those patients with an overall good (“mild-moderate”) 
metabolic control as determined by an HbA1c ≤ 8.4% compared to those who have poor 
glycemic control. At HbA1c levels < 7.3%, PPH contributed ~70% to the HbA1c value, 
thus suggesting the importance of effective PPG management for an optimal long-term 
metabolic control in diabetes patients. Three years later, Slama et al. also reported that in 
their sample population of T2DM patients, PPGEs accounted for an average of 40% to 
the total “abnormal hyperglycemia”, which in turn contributed to about 1% absolute rise 
in HbA1c values.13 They also emphasized the contribution of PPGEs to the overall 
glycemic control of patients with a more controlled HbA1c. These studies point to the 
importance of controlling PPGEs and not only fasting glucose levels in patients with 
diabetes to maintain a good glycemic control and avoid morbidity and mortality 
associated with the disease.  
 Besides its contribution towards the overall glucose control, PPH was also shown 
to be an independent risk factor for macrovascular complications associated with diabetes 
by the STOP-NIDDM (Noninsulin-Dependent Diabetes Mellitus) trial in 2003.9  The 
study demonstrated that an alpha-glycosidase inhibitor, acarbose, which is an anti-
diabetic drug that interferes with the metabolism of carbohydrates and thus normalizes 
postprandial plasma glucose concentrations, reduced the incidence of cardiovascular 
diseases (CVD) and hypertension. Patients with impaired glucose intolerance who 
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received treatment with acarbose had a significantly lower risk of developing CV events 
including coronary heart disease, cardiovascular death, congestive heart failure, 
cerebrovascular events and peripheral vascular disease with a hazard ratio (HR) of 0.51 
(95% CI, 0.28-0.95; P =0.03) when compared to those receiving placebo. These patients 
also had a significantly lower risk of developing hypertension (HR = 0.66; 95% CI, 0.49-
0.89; P = 0.006). 
  In addition, both Ceriello and Home described the role of PPH as a risk factor for 
microvascular changes in their review articles.7,11 Their theory behind the association of 
PPH and vascular events is that it has a modifying effect on most of the cardiovascular 
risk factors such as LDL oxidation, thrombosis activation, and endothelial dysfunction. 
Increased oxidative stress or the overproduction of the reactive free radical molecule 
superoxide secondary to hyperglycemia is described to be the unifying mechanism to all 
of these risk factors.19-21 Monnier et al. in 200615 and recently (2013) Wu and associates16 
showed that acute glucose fluctuations have a direct correlation in the activation of 
oxidative stress in T2DM patients and newly diagnosed children with T1DM,  
respectively. These studies even more signify the deleterious effect of PPH and its 
contribution to the vascular complications associated with diabetes. Therefore, more 
studies targeting interventions to moderate unnecessarily elevated and prolonged PPGEs, 
which contribute to glucose variability in both type 1 and 2 diabetic patients, are needed. 
Shortcoming of Current Management of T1DM with Rapid-Acting Insulin Analogs: 
Postprandial Hyperglycemia 
 Insulin therapy has been the key player in the control of hyperglycemia in patients 
with T1DM and at the later stages of T2DM since the early 1920s.22 However, until the 
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discovery of RAIAs, an insulin therapy that most closely mimics the fast physiologic 
insulin response seen in healthy individuals was not available. What was considered to be 
the best insulin therapy at the time, regular human insulin (RHI), did not reach peak 
serum levels until 2-3hrs after subcutaneous injection, which is significantly delayed in 
relation to the time to peak postprandial serum glucose levels.23 RAIAs, on the other 
hand, reach maximal concentration in the blood in about 1hr and have a peak glucose 
lowering effect ~90-120min after SC injection. 
 One of the first studies in 1996 comparing RAIAs, specifically lispro to RHI by 
Heinemann et al. showed that after a carbohydrate-rich meal in T1DM patients, there was 
a significantly less prandial glucose excursion with insulin lispro vs. RHI (9.9±1.4mmol/l 
vs. 11.9 ± 2.8mmol/l; P < 0.05).24 Also, there was a rapid peak plasma insulin 
concentration at 68 ± 18min to a level of 369 ± 73pmol/l after SC injection of lispro vs. 
the slow insulin rise to 263 ± 59pmol/l within 116 ± 27min with RHI injection (p < 0.01).  
This study along with others23,25-31 have demonstrated that RAIAs have a significantly 
faster absorption rate, peak plasma concentration, faster peak glucose lowering effect and 
shorter duration of action. These properties markedly improved the coverage of prandial 
blood glucose spikes with close resemblance to the mealtime physiology seen in people 
without diabetes. The shorter duration of action of RAIAs also minimized the incidence 
of postprandial hypoglycemia that was significant with RHI. RAIAs, therefore, have been 
incorporated and are routinely used as part of the standard of care for patients with 
T1DM.  
 Currently there are three kinds of FDA approved RAIAs available for treatment of 
diabetes: insulin lispro, aspart and glulisine. A review article by Home P.D. examined the 
 20 
possible clinically significant differences in efficacy, tolerability, safety and treatment 
satisfaction that might exist between these three RAIAs. After a systematic analysis of 19 
articles, the author recognized a slightly faster onset of action for insulin glulisine. 
Nevertheless, no other significant differences between the three RAIAs in terms of their 
pharmacokinetic and pharmacodynamic profiles were identified. The faster onset of 
action of glulisine has not been shown to have any clinically significant benefit in terms 
of overall glucose control or treatment satisfaction.32   
  As part of the standard of care for T1DM, RAIAs have offered an immense 
clinical benefit in optimizing postprandial glucose excursions. However, the need for an 
even better control with an injection-meal interval (IMI) was recommended by follow-up 
studies, as postprandial blood glucose levels were still above target ranges.33,34 Compared 
to the normal physiologic conditions, the relatively delayed absorption of SC injected 
RAIAs is recognized as the obstacle. A randomized crossover trial by Luijf and 
associates has shown that insulin aspart administered 15min before a meal has a 
significantly lower PPG and peak glucose value when compared to a 0min and -30min 
treatment arms (P = 0.038).34 Another study by Cobry et al. has demonstrated a similar 
reduction in postprandial excursions with use of RAIAs, specifically glulisine.33 When 
administered 20min before a standardized meal in patients with T1DM, glulisine showed 
a significantly lower glycemic excursion 60 and 120 minutes after meal initiation than 
when administered immediately before or 20min after the meal. (At 60min - 180.3 ± 
66.4mg/dL vs. 222.0 ± 58.9mg/dL [P = 0.0029] and 235.7 ± 46.6mg/dL [P = 0.001]; at 
120min - 176.3 ± 70.7mg/dL vs. 207.7 ± 48.5mg/dL [P = 0.0294] and 205.8 ± 50.7mg/dL 
[P = 0.0408], respectively). The pre-meal injection group also had significantly lower 
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blood glucose levels under the postprandial goal of < 180mg/dl compared to the at-meal 
and post-meal injection group (P < 0.0001 for both).33 These studies, beyond 
demonstrating the benefit of RAIAs in reducing PPG, emphasized the need for an 
appropriate injection-meal interval (IMI) to compensate for the delay between 
subcutaneous (SC) injection of insulin and its onset of action.  
 Patients are therefore strongly advised to take their pre-meal insulin injections on 
an average of 5-15 minutes before mealtime. The current administration guidelines in the 
U.S. recommend aspart to be injected 5-10min before a meal, lispro 15min before or 
immediately after a meal and glulisine 15min before a meal or within 20min after starting 
a meal.35-37  Even though these guidelines are in place, many T1DM patients do not 
adhere to these recommendations in their daily life due to impracticality.38 This IMI is 
also potentially detrimental as it could cause hypoglycemia in situation where meal is 
delayed after the pre-meal administration of an RAIA (e.g. in a restaurant setting). Such 
pre-meal dosing practices will be even more dangerous if patients have pre-meal blood 
sugars in the low side of the normoglycemic range.39 
Additional Challenges in Controlling Post-meal Blood Glucose: Overweight and 
Obese Adolescent with T1DM 
 In the last 10-15 years the prevalence and clinical implications of the vastly 
increasing overweight and obese children and adolescents with T1D have become a focus 
of many studies. A retrospective study by Libman and associates in 2003 reported that 
the prevalence of being overweight and obese in African American and Caucasian 
children at the onset of T1DM has tripled from 12.6% in the 1980s to 36.8% in the 1990s 
(P=0.0003).40 According to their analysis at the time, this prevalence rate went hand in 
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hand with the increasing prevalence of obesity in the general population. Two articles 
that described the BMI distribution of a diverse group of T1DM children and adolescents 
in comparison with the general population identified that currently there are about 11-
13% overweight and about 21-22% obese (total of about 34%) children and adolescents 
with T1DM compared to ~33% of youth without diabetes. 41,42 
 The challenge of achieving optimal PPGEs is even more pronounced in this 
increasingly obese and overweight pediatric population with T1DM. Besides all the other 
factors that interfere with the effective absorption of SC injected insulin analogs in non-
obese individuals, this population will have an added obstacle of increased subcutaneous 
fat. It has been shown that increased subcutaneous fat thickness has a negative correlation 
with the absorption of SC injected insulin analogs.43 de Galan et al. comparing the 
efficacy of needle-free jet RAIA injection with a conventional insulin pen in overweight 
and obese individuals without diabetes demonstrated that higher body weight indices are 
associated with a delayed insulin absorption and onset of action when administered 
through a conventional insulin pen.44 Also, obese and overweight individuals have an 
increased insulin resistance impairing exogenously injected insulin’s action,45 which 
further contributes to the difficulty of maintaining normoglycemia.   
 Part of the pediatric population is the adolescent children in their prime time of 
puberty. This particular group has been shown to have an increased insulin resistance and 
the DCCT has demonstrated that near-normalization of blood glucose levels was more 
difficult in adolescent subjects as compared to adult subjects with T1DM.46 As expected, 
the HbA1c levels for the adolescent group was higher than the adult subjects with 
T1DM.46-48 According to the 2012 review article by Cree-Green et al.,45 the surge in 
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pubertal hormones such as estrogen, testosterone and growth hormone as well as the 
greater fat mass in the adolescent population plays a big role in the decreased insulin 
sensitivity seen in T1DM as well as non-diabetics in the pubertal age. The obese 
adolescent population therefore seems to require a larger pre-meal insulin dose to avoid a 
higher and longer PPH and attain a good overall glycemic control.47  
Approaches Currently in Clinical Development to Control Postprandial Glycemic 
Excursions 
 Faster acting insulin will mimic physiologic insulin response better and will lower 
blood sugar immediately. Several investigators have developed interest to find such 
ultrafast-acting insulin and many studies have been underway since before the discovery 
of RAIAs. Currently, there are several mechanical and insulin formulation based 
approaches that are at different stages of clinical development. Some of the current 
mechanical approaches include the use of a warming device to increase local blood flow, 
use of needle-free jet injectors or application of an enzyme to spread the insulin into a 
wider area in the SC tissue and the use of microneedles to inject insulin into a more 
vascularized layer, the dermis. The formulation approach comprises studies that play with 
the insulin formulation to find “novel insulin analogs” by adding excipients that either 
increase blood flow to the area or promote the breakdown of the hexameric RAIAs.49 Out 
of all these approaches, the warming device, the enzyme, recombinant human 
hyaluronidase (rHuPH20), and microneedles have so far shown some promising results. 
(Refer to Table 1 for some studies reviewed). 
 InsuPatch (InsuLine Medical. Petach-Tikva, Israel) is a small warming patch 
devised and approved for use in Israel. It is supposed to warm the local skin injection site 
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to a temperature of 38 °C and increase blood flow to the SC tissue by a mechanism of 
vasodilation.  This device has been proven to increase the absorption of subcutaneously 
injected insulin analogs by various studies. 49-52 It is also safe and well tolerated by 
patients.  Cengiz et al. demonstrated that the bioavailability of insulin aspart was 
improved by 28% with the use of InsuPatch and showed a significantly enhancement in 
aspart’s pharmacokinetic profile (Cmax, P=0.04  & Tmax, P=0.03).52 This study also 
showed a significant (TGIRmax; P=0.002) improvement in the time to peak action of 
aspart. However, there was no clinically significant change in the peak action of the 
insulin analog between the two groups. The authors attribute this lack of 
pharmacodynamics improvement to the specific characteristic of the population used, as 
adolescents in the pubertal age have been shown to have a greater insulin resistance, 
which might have “blunted” the expected results.52 This theory is supported by the study 
of Raz and associates in 2009, who performed a meal tolerance study in an adult 
population investigating the effect of InsuPatch in the action of RAIAs.50 There was a 
significant enhancement in insulin Cmax (P<0.05) and a reduction in the Tmax (P<0.05) 
demonstrating an improved PK profile. This study did not use the euglycemic glucose 
clamp technique to analyze the PD profile of RAIAs, but by sampling the plasma glucose 
after a meal challenge, they were able to determine the PPG concentrations. There was a 
significant reduction (~40%) in the peak glucose excursion 90min after the meal 
(74±48mg/dl vs. 121±43mg/dl; P<0.005) in the group using InsuPatch vs. the group not 
using it.   
 The other mechanism that has shown good PK and PD improvements in the 
currently available RAIAs is recombinant human hyaluronidase.  Hyaluronidase is an 
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enzyme that transiently disrupts hyaluronan, which is “the component that confers a gel-
like consistency to” the SC extracellular matrix, “limiting the spread of injected materials 
to the process of diffusion.”49 This product is approved by the U.S. Food and Drug 
Administration (FDA) and has been utilized as an additive in other injectable medical 
fluids for its absorptive properties. Hompesch and associates, using an individually 
optimized dose of RAIA or RAIA plus hyaluronidase, performed a liquid meal challenge 
study in T2DM adults. Their study showed the effectiveness of hyaluronidase in reducing 
PPG within 2 hours after a meal challenge (159±31 vs. 138±32mg/dl; P=0.0098) in those 
who received lispro with rHuPH20 vs. just lispro.53 A similar study in T1DM adults 
showed a significant reduction in the peak of total glycemic excursions (P=0.002) in 
those who had hyaluronidase coadministered with lispro vs. those without 
hyaluronidase.54 
 Microneedles are short-length needles that directly infuse insulin into the dermis 
without reaching the SC tissue. Since the dermis is a more vascularized space compared 
to the SC tissue, by injecting insulin intradermally, Gupta and colleagues hypothesized 
that insulin absorption will be accelerated and postprandial hyperglycemia will be well 
controlled.55 This hypothesis has since been proven true by a few studies55,56. Even 
though they had a small sample size of only 5 T1DM patients (2 adults, 1 adolescents and 
a child), Gupta et al. were the first to demonstrate a significantly faster absorption of 
insulin (P=0.01) as well as a markedly improved post-meal excursion of glucose (with an 
unspecified significance) in those who received lispro with a microneedle compared to 
those with SC insulin infusion. There were no significant changes seen in the peak insulin 
level (C-INSmax) and bioavailability of the insulin (AUCINS).55 
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 Even though most of the above mentioned approaches and more have shown 
promising results towards finding ultra-fast acting insulin, there is not yet one approach 
that is approved and incorporated into the daily management of T1DM patients in most 
parts of the world. Even when approved, the complexity of most of these approaches 
might make them costly and not as easily accessible to the majority of the population 
who needs it. This will especially be evident in developing countries where even the most 
up-to-date RAIAs are hard to locate. Therefore, more studies are needed to look for 































Table 1. Insulin pharmacokinetic and pharmacodynamic profiles following RAIA 
administration with or without a specific intervention.  
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Local Skin Massage as an alternative approach to mitigate PPG  
 Massaging the local insulin injection site is one promising approach that was 
explored before the invention of RAIAs.57-59 Until today, to our knowledge, only one 
study has investigated and described the potential benefit of massaging SC insulin 
injection site on the PK and PD profiles of insulin, specifically in patients with T1DM. 
This study was done by Dillon in 1983, and it used as an intervention a 3-minute massage 
15 minutes after the administration of insulin vs. no massage to assess the benefit of 
massaging on the bioavailability of SC injected insulin.57 The study was done on 8 lean 
insulin-dependent diabetic individuals (1 adolescent and 7 adults) who had a relatively 
well-controlled glucose profiles and were using low doses of mixtures of regular and 
intermediate insulin. The patients were in a fasting state throughout the study during 
which blood glucose, free and total plasma insulin levels were sampled for four 15-
minute-intervals on both the control (no intervention) and intervention days. A significant 
increase from baseline in plasma free insulin level was seen 30 minute after massage 
(45min after SC injection) on the day of the intervention vs. no-intervention (4.5 ± 1.8 vs. 
14.7 ± 3.7microU/ml; P < 0.05). At the same time, a significant (p < 0.05) fall in serum 
glucose level was seen with an 8.3% lower blood glucose change from baseline in those 
who received the massage intervention suggestive of more potent insulin action after 
massaging the insulin injection site.  
 Even though this study has contributed vital information for its time, it has many 
limitations that make it less generalizable and inconclusive regarding the current issues 
with RAIA therapy discussed in this chapter. First and foremost, the study had a very 
small number of participants, 8 subjects. This, as it is for any randomized controlled 
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studies, blunts any significant changes that might have been detected. Secondly, the data 
collection for glucose and insulin levels was done in a very wide time interval. This also 
might have reduced the chance of identifying a much faster insulin peak and glucose 
lowering effect. Thirdly, the patients were taking their own home dose insulin mixture of 
intermediate and regular insulin and the increase in free and total insulin absorption 
observed in the study could be of either insulin. This makes it hard to discern if regular 
insulin or intermediate insulin should have been the target of further investigation 
probably accounting for the reason why other studies have not been done in this area. 
Considering that regular insulin takes up to 2-3 hours to reach peak levels, and longer to 
show glucose reducing effect, the study also failed to assess full PK profile of the injected 
insulin as samples were taken only for 45 minutes after SC injection.   
 Dillon’s study speculates that the mechanism behind improved insulin 
pharmacokinetics seen in T1DM patients is the increase in blood flow to the area of 
injection as well as improved insulin delivery to the circulation through the lymphatic 
system.57 In their recent review article Heinemann and Muchmore also discuss this 
probable increase in local blood flow following massage just as seen with increased 
ambient skin temperature43,50,60 A review article discussing the physiology behind the 
therapeutic effects of massage also supports this theory and discusses that massaging 
results in the vasodilation of superficial blood vessels and increases blood flow to the 
area of the massage.61 For light pressure massages, the vasodilatation is thought to be a 
result of local axonal reflexes. However, for deeper massages histamine release plays a 
big role in the vascular response that is achieved. These authors also discuss the 
“uncomplicated” mechanism in regards to the theory of improved lymphatic drainage 
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associated with massaging.61 Massage compresses superficial lymph veins promoting 
their drainage, and this in turn, opens up space in the vessels for interstitial fluid to drain 
into. This improved lymphatic draining by itself could be one contributing factor for the 
fast absorption of insulin, but additionally, the decreased pressure in the interstitial space 
is indicated to reduce arterial congestion further improving perfusion in the area.58,61  
 This variety of possible mechanisms of action makes massage an appealing 
approach to pursue in the attempt to find a faster acting insulin analog. Even though 
Dillon’s work has many limitations, we speculate that with new controlled studies 
particularly utilizing RAIAs, massaging local injection site could provide a cost-effective, 
non-invasive, practical and easily accessible approach to facilitate insulin absorption and 
improve PPH in T1DM patients. To the best of our knowledge, there are no data on the 
benefit of this approach in overweight and obese T1DM adolescents in regards to RAIA 
pharmacokinetics and pharmacodynamics. In the high-risk overweight and obese 
adolescent population, such an intervention that could accelerate exogenous insulin 
action will have paramount role. Not only will it improve the daily or acute plasma 
glucose fluctuations that have a significant contribution to the late-stage complications 
associated with T1DM, but also improve the overall glycemic control (HbA1c) of this 
population.  
Review of Relevant Methodology  
Study design, randomization and blinding 
 This proposed study will be a randomized, controlled, single-blinded, crossover 
euglycemic clamp study. As illustrated by the studies reviewed in this chapter50,52-56, 
crossover trials are the standard for testing the time-action profiles of rapid-acting insulin 
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analogs. Crossover study designs, if done with randomization of intervention orders, are 
known to be the strongest possible approaches to control for participant characteristics at 
a study design level. However, this approach should not be used if a carry-over effect is 
expected from one intervention to the next (control to active intervention or vice versa)62. 
In our study, we do not suspect any carry-over effects from the control intervention to the 
massage intervention as the SC infused insulin has a transient effect wearing off in the 5-
8 hour clamp study duration. In regards to carry-over effects from the massage 
intervention, we believe it is unlikely, but since there are no recent studies that validated 
the exact mechanism behind the effect of local skin massaging on the insulin absorption 
and action profiles, we will allow for at least a week of washout period between the two 
intervention study days.   
 Another limitation of a crossover design is a history threat to the internal validity 
of the study. This is any external event that could potentially occur simultaneously with 
the independent variable and alter the outcome of the study. The event could 
differentially affect the subjects during the two intervention orderings, therefore, it is 
crucial to keep controlled and similar settings on both study days. Since temperature has 
been shown to hasten SC injected insulin absorption, we will perform the clamp study in 
a temperature-controlled room (22-24°C).50,51,60 Additionally, the same conventional pen 
will be used for both injection days for each subject to avoid any variability. 
 We propose to use the euglycemic clamp technique, first described by Defronzo 
et al.63, to determine our PK and PD end points described in Chapter III of this proposal. 
Even though there are other approaches that have been validated to measure insulin 
sensitivity including the insulin tolerance test (ITT), the oral glucose tolerance test 
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(OGTT), and frequently sampled intravenous glucose tolerance test (FSIVGTT), the 
euglycemic clamp technique is considered the gold standard test for insulin action in our 
population.63,64 Besides the recent review article that reconfirmed this, many studies have 
utilized this test to determine insulin time-action profiles in diverse populations with 
optimal results.30,52,65 The technique uses an approach to measure the true tissue 
sensitivity to insulin by maintaining a steady-state euglycemia throughout the study.63 At 
steady plasma glucose levels, the glucose infusion rate following the exogenous insulin 
infusion will reflect the actual glucose uptake by peripheral tissues.  
 In the proposed study, allocation of intervention days will be randomized in order 
to prevent selection bias. Due to the nature of the intervention, massaging cannot be 
concealed from the study subjects and investigators in the room. However, data-analysts 
will be blinded to the treatment allocation. Additionally, the study outcomes, both 
primary and secondary, are objective measures of RAIA PK and PD profiles and should 
not be influenced by blinding.66  
Study population, sampling and recruitment  
 The target population for this study is overweight and obese adolescents between 
the ages of 12-18 years who have a diagnosis of T1DM for ≥ 1 year at the time of 
enrollment. Inclusion and exclusion criteria for enrollment are listed in chapter III of this 
proposal and are based on literature reviewed in this Chapter. The age range for the study 
participants, 12-18 years, is chosen to avoid variability due to insulin sensitivity 
differences among study subjects. It has been shown that teenagers in puberty have an 
increased insulin resistance (IR) compared to the rest of the pediatric population.45,48,67 
Swan et al.48 showed that there is an ~37% delay in the PD response of SC injected 
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RAIAs, specifically aspart, in the pubertal age compared to the pre-pubertal age group. 
The pre-pubertal group had a significantly higher glucose infusion rate requirement 
(1,326 ± 131mg/kg vs. 964 ± 65mg/kg; P<0.01) indicating better insulin sensitivity. A 
longitudinal study of insulin sensitivity also demonstrated that during puberty there is an 
~50% decrease in insulin sensitivity67. The rise in this IR begins around age 7, peaks 
before Tanner stage II and normalizes at the end of puberty.68 Therefore, we will only 
include adolescents between Tanner stages III-V.  
 Participants will be recruited from the Yale Pediatric Diabetes Clinic. Since the 
study subjects will be sampled from a single-center, it was important for us to determine 
the availability of the source population. Combining data collected from a pediatric 
endocrinologist at the clinic and data from the T1D registry,69,70 we have identified a 
minimum of 168 obese and overweight 12-18 year-old adolescents, which is 
approximately 12% of the total pediatric patients at the clinic. Even with a limited source 
population, we do not anticipate any obstacles, as our needed sample size is relatively 
small (discussed later in this chapter).  
Intervention and Safety 
 SC injection of aspart, one of the three FDA approved RAIAs, is the only 
proposed intervention for the control day of the study. The same insulin analog and dose, 
in addition to the 3-minute massage, will be used for the intervention day. In 2012, a 
systematic review of 19 articles by Home P.D. reported an equal efficacy and safety of all 
three RAIAs.32 However, these insulin analogs exhibit small clinically insignificant 
variability in their PK and PD profiles including peak insulin concentration, time to 
maximal concentration, onset of action, and duration of action.35-37 Thus, in this proposed 
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study we will only use one type of RAIA, aspart, to avoid any inter and intra-subject 
variability in insulin absorption and action. In addition, even though not significantly 
different, aspart has a faster onset and peak action, as well as a shorter duration of action.  
 The prescription information for aspart lists potential adverse effects of 
hypoglycemia, hypersensitivity and local injection site reactions, lipodystrophy, rash and 
pruritus35. In 1998, a randomized double-blinded crossover trial in T1DM patients 
comparing the glycemic control benefit of insulin aspart with RHI also identified a few 
adverse events, including, hypoglycemia episodes, fatigue, anorexia, vomiting and 
pyrexia.26 Mild to moderately severe hypoglycemia and headache were also noted in 
another randomized double-blinded crossover trial comparing RHI with aspart27. These 
events however were noted consistently between both RHI and aspart. Also, recent trials 
that used aspart in their study do not report any such adverse effects.44,52,65 Throughout 
the study, we will keep in mind these potential adverse events that might present 
associated with aspart use. We will also cautiously perform a pre and post-study history 
and physical exam in all our participants.  
 In choosing the site of SC insulin injection, we looked at two studies in particular 
along with recent trials that utilized the euglycemic clamp technique. Mudaliar et al., 
comparing the abdominal site to the deltoid and thigh, showed a significantly shorter 
duration of glucose lowering action (~34min shorter; P < 0.001) in healthy, non-diabetic 
men who received aspart vs. RHI in a randomized crossover euglycemic study28. This 
study also demonstrated a 10-14% lower total glucose infusion rate (AUCGIR) when 
aspart was injected abdominally vs. in the thigh or deltoid region. In addition to this 
study, a randomized crossover trial using lispro71 has also shown some PK property 
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differences between the abdomen and other two sites, though not significant. Based on 
these data suggesting an optimal insulin action for RAIAs injected abdominally, we have 
chosen the abdomen for SC aspart administration.  
 In regards to the euglycemic clamp study, as suggested by Brown and Yanovski,64 
skilled investigators who have extensive experience and clinical judgment in adjusting 
the glucose infusion rates will be utilized in the study. In addition, a validated computer 
algorithm will be available to assist with the decision-making. Other personnel involved 
in the study will also be experienced physician assistants. They will continually monitor 
the patency of the IV lines to avoid infiltration, and also for any patient symptoms and 
signs of hypoglycemia. 
Massage  
 Due to lack of prior clinical trials that determined an optimal rate and pressure of 
massage associated with the study’s dependent variables, a standard slow rate of 
30cycles/minute and firm pressure will be used to standardize our intervention. This is 
adopted based on the information in the review article of manual massage techniques by 
Goats.72 This article states that a slow yet firm pressured massage technique known as 
effleurage is identified to increase blood and lymph flow to massaged tissue. 
 There are no reported adverse effects associated with the use of massage for the 
purpose of facilitating medication absorption. The only study of massage in T1DM 
patients reports no adverse effects.57 But, it is not clear if this is because there were none 
observed or if the effects were not simply measured as part of the original plan. Another 
study that performed a 30 minute long massage in non-diabetes patients also reports no 
adverse effects.58 This study obviously used a much longer massage period from that of 
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the proposed period on this study. We are, therefore, confident to say that we don’t 
expect any major adverse effects associated with our standardized massage intervention.   
Potential confounders and inclusion and exclusion criteria: 
 It is important to consider injection site subcutaneous fat thickness as an inter- 
and intra subject confounding variable to the proposed study. The negative correlation of 
SC fat with insulin absorption has been discussed previously on this chapter43,44 and 
considering our sample population’s body weight, it’s likely that most of our subjects will 
have a substantial amount of abdominal fat, and this will vary between subjects and also 
from one site to another in a subject. Therefore, the same abdominal injection site will be 
used on both intervention days and this will be 10cm horizontal to the umbilicus on either 
side.  This will exclude the intrasubject confounding effect of SC fat. The thickness of SC 
fat layer at the injection site will be estimated for each subject using an ultrasonography 
and if a significant variability is noted we will include SC fat subgroup analysis to 
account for a possible intersubject variability. 
 Insulin dosing among the study subjects will be determined based on their body 
weight. Insulin concentration, however, will be kept the same among all subjects at 
0.2U/kg. This is to avoid any intersubject variability of end point measures, as studies by 
Sindelka et al. and others have shown a delayed insulin absorption and reduced serum 
insulin concentration associated with higher concentrations of insulin administered 
SC.43,73 Although our obese population might require high insulin doses that could show 
a modest prolongation of action of aspart, studies assert the insignificance of this as a 
possible confounder.74,75 
 Strenuous exercise has an effect on the insulin sensitivity of peripheral tissues, 
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most significantly the muscle tissue. Acutely, during and right after an intense exercise, 
there is an enhanced utilization of muscle glycogen stores, which facilitates insulin-
assisted muscle glucose uptake76,77. This has a significant influence on the glucose 
lowering effect of insulin therapy. Long-term training also determines insulin action 
profiles, as there is an overall improved glucose metabolism.78 Therefore, exercising is 
one possible confounding variable for our study, especially since adolescents might be 
more motivated to enroll in strenuous training programs. We have eliminated the short-
term effect of a strenuous exercise by including a no-exercise inclusion criterion at least 
48 hours before the study dates. However, it is difficult to eliminate any modifying effect 
a long-term exercise routine might have in our study design.  
 Many studies have demonstrated the effect of ambient and local skin temperature 
on the rate of insulin absorption. With increased surrounding temperature whether as a 
result of sauna60, or local heat application to site of injection50-52, the absorption and 
action of insulin is significantly increased due to increased blood flow to the skin. 
Therefore, if not adequately controlled for, room temperature could differentially affect 
subjects in the two intervention orderings. Our study will be performed in the same 
temperature-controlled room on both intervention days.  
 Lastly, any medications and behaviors that interfere with insulin action, glucose 
metabolism or skin blood and lymphatic circulation such as corticosteroids79, smoking80, 
caffeine intake81 and more are controlled for through our inclusion and exclusion criteria.   
Sample size calculation 
 Sample size (SS) is determined based on the expected difference between the 
treatment and control groups on the measure of our PK primary outcome - rapid-acting 
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insulin analog absorption rate (T-INSmax). Since there are no prior clinical trials 
specifically examining the efficacy of local site massage on the PK and PD properties of 
RAIAs in overweight and obese T1DM adolescents, the expected effect size for our study 
was extrapolated based on data from previous relevant studies.  
 First, we evaluated a randomized crossover trial investigating the efficacy of a 
local site warming device, a mechanistically similar approach to that of massage, on the 
absorption of SC injected insulin aspart in normal weight and overweight T1DM 
adolescents. In this study, an absolute difference of 26 min and a relative reduction of 
~39% in the time to maximal insulin concentration (T-INSmax) was observed between 
the group with the activation of the warming device at the SC injection site and without 
the warming device.52 Moreover, a randomized, controlled crossover study showed that 
the absorption of SC injected insulin aspart using a conventional pen is delayed among 
overweight healthy adults when compared to their non-overweight counterparts by 
~30min (95% CI 13.7 – 48.5; P < 0.012), which represents a relative delay of ~37.5%. 44 
This delay in aspart absorption in this population is consistent with that of the obese 
population. The aspart insulin prescription information for obese healthy individuals 
describes the median time to maximal insulin concentration is ~85min compared to 
~60min in non-obese individuals.35 In addition, a randomized, controlled crossover trial 
comparing the PK and PD properties of glulisine and aspart showed a delayed absorption 
of aspart in obese adults with type 2 diabetes, with a T-INSmax of 93min.82  
 Based on this data, we estimate that the smallest relative reduction of time to 
maximal insulin concentration for our study population would be 39%. To be 
conservative, our sample size calculation assumes the lowest possible absolute difference 
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in the time to peak insulin concentration between our intervention and the standard of 
care. Therefore, we estimated we will need 19 subjects to detect an absolute mean 
difference of effect of 33 ± 41minutes to achieve 90% power and 2-tailed significance 
level of 5%. The absolute difference is deduced from a 39% reduction of effect from 85 
minute. The standard deviation is adapted from Cengiz et al.’s randomized, controlled 
crossover trial52. Based on this same study, an attrition rate of 7.7% was determined, but 
to be conservative, we have accounted for a loss of 20% of patients/data. This will add 4 
more subjects to our sample size resulting in a total of 23 participants.  
Conclusion: 
 Based on the literature analyzed in this chapter, there is strong evidence that the 
obese and overweight adolescents have a significant challenge in achieving good 
glycemic control and also avoiding daily glycemic variability. Unfortunately, there have 
not been many studies that investigated the benefit of potentially faster-acting insulin, 
with an accelerated absorption and action, on this particular population. PPH being one 
main contributor to the morbidity and mortality associated with T1DM, we will seek to 
investigate injection site massage as a potential solution by improving the PK and PD 
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CHAPTER III: STUDY METHODS 
Study Design:  
 This proposed study will conduct a single-centered, data analyst-blinded 
randomized crossover trial to investigate the pharmacokinetics and pharmacodynamics of 
aspart with or without a 3-minute abdominal SC injection site massage. All participants 
will undergo two euglycemic glucose clamp experiments in an inpatient, controlled 
setting where they will be admitted for a 24-hour period at a time. On the first day of the 
study, subjects will be randomly assigned by a computer program to begin with either SC 
aspart injection (control intervention) or SC aspart injection plus a 3-minute massage at 
an abdominal injection site, 10cm horizontally from the umbilicus (active intervention). 
On the second day of admission, participants will switch interventions. The insulin aspart 
dose that will be injected during each admission will be identical. There will be a 
washout period of at least 1 week between the two clamp studies. Female subjects will be 
tested at 4-week intervals to ensure that experiments take place during corresponding 
periods of the menstrual cycle.  
Study Population, Sampling and Recruitment: 
 A total sample of 23 male and female overweight and obese adolescents with 
T1DM will be recruited from the Yale Children’s Diabetes Clinic for the purpose of this 
study. The study will be announced to all the on-site clinicians through a meeting where 
detailed description of the study will be communicated. These clinicians will in turn 
approach patients who meet the inclusion criteria and provide them with the study 
description, risk and benefits, consent procedures and privacy protection policy. Patients 
who agree to participate will then be prescreened for exclusion criteria eligibility by 
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participating investigators. Once eligibility is confirmed, investigators will go through the 
consent process with participants again to ensure that they have been well informed. 
During this process, investigators will explain the nature of the intervention, the need for 
hospitalization for 24 hours (the period of the study) on two different occasions and 
address any concerns the subjects might have. 
 Subjects will be eligible to participate in the study if they fulfill the inclusion and 
exclusion criteria listed below: 
Inclusion Criteria: 
• A clinical diagnosis of T1DM for ≥ 1 year  
• On insulin therapy for at least 3 months 
• Age between 12 and 18 years old 
• BMI percentile that is ≥ 85%  
• Hemoglobin A1c (HbA1c) < 10.0%  
• Non-smoker 
• Able to abstain from alcohol, coffee and strenuous physical 
exercise at least 48hrs prior to study date 
• The ability to comprehend both written and spoken English 
 
Exclusion Criteria:  
 
• Any other chronic disease besides T1DM 
• On any medication that might interfere with the absorption of 
insulin or affect glycemic control such as glucocorticoid therapy 
• On any new medication affecting blood glucose metabolism such 
as oral anti-diabetic drugs, or antipsychotic drugs in the last month 
• Pregnancy or breast-feeding 
• Any medical or psychosocial condition that might compromise the 
adolescent’s or parent’s ability to make an informed consent 
• Any skin diseases that affect skin blood flow 
• HbA1c > 10% to eliminate the effect of poorly controlled diabetes 
Subject Protection and Confidentiality: 
 Parents of all participants (age < 18yrs) will be given written informed consents 
(Appendix A) prior to the beginning of the study. We will also obtain an informed assent 
from all the adolescent subjects (Appendix B). To protect the confidentiality of the study 
 48 
participants, the proposed study will first be submitted to the Pediatric Protocol Review 
Committee (PPRC). Once it’s approved, the study will proceed according to the 
guidelines and regulation of the Human Investigation Committee (HIC) and the Health 
Insurance Portability and Accountability Act (HIPAA). Subject identifying information 
will be kept confidential during and after study completion per Yale University Research 
Regulation. All collected data will be de-identified with the use of specific subject 
identification numbers assigned to each individual during enrollment. Data entry and 
analysis by data analysts and investigators will be performed and stored in secure 
databases on Yale’s encrypted computer systems. Access to research data will only be 
available to investigators and analysts who have special passwords. The principal 
investigator will be responsible for identifying this personnel and protecting subject’s 
personal information.  
Study Variables and Measures: 
 The independent variable is a 3-minute injection site massage after SC injection to 
the abdomen 10cm on either side of the umbilicus. The control variable is an abdominal 
SC aspart injection also 10cm from the umbilicus.  
 The primary pharmacokinetic end point (dependent variable) is the time to peak 
serum insulin level (T-INSmax). This is a measure of the rate of absorption of insulin 
corresponding to the time when insulin plasma concentration reaches its maximum level 
after SC injection. The primary pharmacodynamic end point is the time to maximal 
glucose infusion rate (T-GIRmax), which corresponds to the time the SC injected inulin 
reaches its maximum glucose lowering effect.  
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 The secondary end points (dependent variables) are also used to expand on the 
assessment of the PK and PD properties of SC injected aspart. The secondary 
pharmacokinetic outcomes will include, the peak insulin levels (C-INSmax) and the total 
area under the curve for change in insulin levels from baseline (AUCINS). The secondary 
pharmacodynamic outcomes will include the maximal glucose infusion rate (GIRmax) 
and the total area under the curve for the glucose infusion rate (AUCGIR 0-300min), which 
is the same as the total amount of glucose administered. All of these parameters will be 
measured and expressed as means ± SEM. 
 Demographic data including their mean daily insulin dose, mean glycemic control 
and duration of diabetes for each subject will be collected at baseline and reported in a 
table.  
Study Protocol/Intervention: 
 Each subject will be admitted to the Yale Hospital Research Unit on two 
occasions for a 24 hour period to undergo a clamp study, which will allow us to 
demonstrate the insulin action properties of SC injected aspart insulin with and without 
injection site massage.  
 All participants will be admitted the afternoon prior to the study day after 
abstaining from caffeine, alcohol use and strenuous exercise for at least 48hrs. The 
experiments will be performed in a temperature-controlled room (22-24°C). Subjects will 
be asked to lie in a supine position in a comfortable bed set up for the purpose of the 
study. Two intravenous catheters will be placed in an antecubital vein of the arms, one 
for blood sampling and the other for the purpose of exogenous glucose infusion. An 
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insulin infusion set will also be inserted in the anterior abdomen on the opposite side of 
the umbilicus from where the insulin bolus will be injected the next day. 
 After an hour of equilibration period, we will begin sampling blood glucose levels 
hourly throughout the night. Using the new insulin infusion set, basal insulin infusion 
will be adjusted as needed to achieve glucose levels between 80 and 120mg/dl at the start 
of the clamp study the next morning. Subjects will fast overnight and continue until the 
end of the 5-hr euglycemic clamp procedure the next day. 
Insulin Action (Clamp) Study 
 On the morning of the clamp study, participants will receive 0.2unit/kg body 
weight bolus of SC aspart insulin at a previously marked abdominal injection site using a 
conventional pen (NovoPen III, Novo Nordisk). Based on their random assignment for 
that study day, subjects will receive the SC abdominal aspart injection with or without 
massage. The administration of insulin begins the 5-hr clamp study and the basal insulin 
infusion will be suspended immediately. Plasma glucose will be maintained at 
euglycemic levels between 90-100mg/dl ± 5% during the study by a variable infusion of 
20% dextrose based on plasma glucose measurements at 5-minute intervals. Blood for 
plasma insulin levels will be collected every 10 minute for the first 90 minutes and then 
every 30 minutes for the remainder of the time. This same procedure will be repeated on 
the second euglycemic clamp study day.  
Massage  
 A physician assistant (PA) participating in the study as a co-investigator will be 
trained to perform a standardized massage after the SC abdominal injection of aspart at 
10cm from the umbilicus. The massage will be performed using three fingers (2nd-4th 
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digits). The PA doing the massage will be trained on human subjects and will adapt a 
standard rate and pressure that will be consistently applied to all study participants. To 
minimize traumatizing friction against the skin, personnel will be trained to massage the 
skin without lifting off fingers to avoid a back and forth movement on the skin. Rather, 
the PA will keep all fingers on the skin and use a circular motion covering a 3-5cm 
diameter from the injection site. A firm pressure adopted from the effleurage manual 
technique of massage will be applied at a rate of 30 cycles/minute. To limit inter and 
intrasubject variability only one person will be responsible for performing the massage.  
Methodology Consideration:  
Blinding: 
 Even thought double-blinded controlled trials are the best in avoiding information 
bias, it is difficult to blind an intervention such as massaging from the study subjects and 
the data-collecting investigator in the room. Therefore, intervention assignments will only 
be concealed from personnel analyzing the data. Data analysts will not be present 
throughout the study, and participants will be instructed not to discuss their group 
assignments with anyone outside of the study room in order to avoid unexpected 
interaction during their inpatient stay.  
Assignment of intervention: 
 Patients will be assigned to a random order of intervention and control day using a 
computer algorithm.  
Monitoring of adverse events: 
 Before the beginning of the study, all participants will undergo a thorough history 
and physical examination by the principal investigator or other PA co-investigators on the 
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study. Patients, who have been using a rapid-acting insulin analog different from aspart 
before this study, will especially be monitored for any potential adverse events reported 
by the producing company including hypoglycemia, hypersensitivity reactions, local 
injection site reactions, lipodystrophy, rash and pruritus. In addition to this, on the day of 
the intervention (local site massaging), subjects will be monitored for any local site 
adverse reaction from the massage such as erythema, edema, and rash. In the unlikely 
case that any of these adverse events occur acutely, intervention will be discontinued 
immediately and patients will pursue an appropriate level of care. The identified event 
will be reported to the Human Investigation Committee.   
Data Collection: 
 During the study, plasma glucose will be measured every 5 minutes using the 
Yellow Springs Instrument (YSI) Glucose Analyzer (YSI Life sciences incorporated, 
Yellow Springs, OH, USA). Blood for plasma insulin levels will be collected every 10 
minutes for the first 90 minutes and then every 30 minutes for the remainder of the time. 
Plasma insulin will be determined by the Mercodia iso-insulin ELISA test, with a 
reported cross-reactivity of 80% with insulin aspart (MercodiaAB, Uppsala, Sweden). All 
these insulin and glucose infusion rate data points will be used to calculate the mean 
values for all the PK and PD parameters for each of the 23 subjects.  
Sample Size Calculation: 
 The number of subjects (N) needed to test out primary hypothesis that local skin 
massage will significantly reduce the T-INSmax and T-GIRmax of SC injected aspart 
with a 90% power and 2-tailed significance level of 5% is N=23. For the given effect size 
mean difference of 33 and SD = 41, a sample size of 19 pairs and alpha of 0.05, the 
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power is 90% to reject the null hypothesis that the difference between groups = 0. Based 
on another euglycemic clamp study, we determined an approximately 7.7% attrition rate, 
but to be conservative, we have accounted for a 20% attrition rate. This will bring our N 
to 23 pairs. The Power Analysis and Sample Size (PASS) software, version 2008 was 
used to calculate the sample size (Appendix C).  
Data Analysis: 
 The study subjects will be their own controls as the study design is a randomized 
crossover, controlled trial. Therefore, there is no need to compare subject baseline 
characteristics between control and intervention group descriptively. However, for the 
purpose of our subgroup analysis demographic data will be collected and categorized.  
 Pharmacodynamic parameters will be derived from the exogenous glucose 
infusion rate (GIR) profiles. Pharmacokinetic parameters will be derived from the serum 
aspart concentrations. All data will be expressed as means ± standard deviation and as 
continuous variables. Distribution of all outcome variables will be evaluated for 
normality. If normally distributed, a parametric test of paired t-test will be used for 
bivariate analysis. Alternative statistical approaches such as the Wilcoxon signed-rank 
test (a non-parametric test) will be used when appropriate if a skewed distribution is 
noted.  PK and PD parameters will be analyzed in subgroups defined by baseline 
characteristics such as sex, race and BMI (overweight vs. obese).   
Timeline: 
 Recruitment of participating adolescents from the Yale Children’s Diabetic Clinic 
will begin in January 2015. All patients who meet the inclusion criteria should be 
contacted by their clinician by the end of the month and will have until the end of March 
 54 
2015 to decide if they want to enroll in the study. This will allot a total recruitment time 
of 3 months. Once enough subjects are recruited, participants will be screened for 
exclusion criteria and those who qualify will go through the consent process between 
April – May 2015. After this, the duration of intervention and data analysis will 
approximately be 6-8 months.  
Table 2. Study timeline of proposed study 
Study Phase Estimated Start Date Estimated End Date 
Submission for PPRC and HIC Review May 14, 2014 -------------------- 
Participant Recruitment January, 2015 March 31, 2015 
Screening/Enrollment April 1, 2015 May 30, 2015 
Study Implementation and Data 
Collection 
June 1, 2015 November, 2015 




CHAPTER IV: CONCLUSION 
Strengths and Advantages  
 This study has numerous strengths in regards to the study design, methodology 
and clinical implications. Primarily, it is going to address an important issue by 
introducing a non-invasive practical intervention to accelerate insulin action. As 
discussed in prior chapters, a few other approaches are in clinical development to address 
the shortcomings of RAIAs in the T1DM population. However, none are as practical as 
massage. Another important strength is our subject group. We are targeting the high-risk 
group of patients (obese, overweight adolescents) who will benefit the most from this 
intervention. Moreover, insulin injection site massaging has never been studied in the 
pediatric patient population, and T1DM is the most common type of diabetes in this 
population1.  
 The greatest methodological strength of this study is its randomized, single-
blinded and controlled crossover design. This is in contrast to the only study that sought 
to look at the benefits of our proposed intervention in T1DM patients and the few others 
done in healthy individuals. The inpatient nature of our clamp study will allow us to 
control for variables that could confound the efficacy of local skin massage. Also, even 
though it is impossible to blind the intervention from the study subjects and investigators, 
we will blind the personnel who will be analyzing our collected data. Our study is also 
superior to other studies as we plan to use a larger sample size, and it will be the first 
study that will utilize the validated, gold standard clamp technique to demonstrate the 
potential of insulin injection site massage after insulin bolus delivery in accelerating 
insulin absorption and action. 
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 The homogeneity of our selected T1DM population is another strength of this 
study. Even though this is usually perceived as a limitation, our study has a specific goal 
and targets only those who we believe will significantly benefit from an uncomplicated 
intervention that has a potential to control PPG levels – the obese and overweight 
adolescents. Additionally, the inclusion criteria for an HbA1c < 10% was specifically 
included as studies have suggested patients with moderately elevated HbA1c values 
above target will benefit more from an optimal control of PPGEs.2,3 The other advantage 
of the homogeny of our subjects is to allow us to accurately determine the effect of our 
intervention. At this preliminary stage, we cannot assume that the efficacy of massaging 
will be consistent among different groups. Therefore, the narrower the differences 
amongst our subjects, the more focused our inferences will be.  
 Another strength of this study is the use of a novel standardized massage protocol 
among all our participants. We cannot attest to this protocol being the most optimal, 
however, this pilot protocol will serve as the basis for further investigations. As it is the 
first study that uses a specific but simple standard massage, we suspect more trials will be 
need to determine the most efficient length, timing, depth, and rate of massage.  Last, but 
definitely important to recognize is Yale’s experience in performing such studies with a 
skilled clinical team. As suggested by Brown and Yanovski4 this is an asset to the safety 
and productivity of clamp studies. 
Limitations and Disadvantages 
 The major limitation of this study is that the euglycemic clamp will only assess 
insulin action properties in a fasting state. Therefore, it will not allow us to directly assess 
postprandial glucose control. We chose not to include a meal challenge test in our design 
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because the goal for this initial study is to serve as the proof-of-concept that massage in 
our particular population can achieve an accelerated insulin absorption and inulin action. 
Additionally, to include a meal study such as one by Hompesch’s group5 (reviewed in 
Chapter II) would require longer study duration, as patients would need to have 
additional visits to determine an individualized optimal insulin dose. This might have 
been difficult to achieve in the 2-year period of time available for this proposed study.  
Nonetheless, as a follow-up to our trial, we strongly recommend the pursuit of a meal 
study to investigate the efficacy of insulin injection site massage in real-life management 
of diabetes. 
 The novelty of our proposed pilot protocol for local skin massage might also pose 
a minor limitation to our study, as it may not illustrate the full potential of the 
intervention. However, this is very unlikely as we are proposing a well-controlled and 
sufficiently powered study that will detect the smallest significant difference between our 
control and intervention groups. We have also standardized the massaging technique 
among all our subjects and will only have one investigator performing the massage.  
Clinical and Public Health Significance 
 The incidence of T1DM and obesity in children are both on the rise.6,7 As 
demonstrated by the recent T1DM Exchange Clinic data, the majority of children with 
T1DM have poor glycemic control.6,7 By increasing tissue insulin resistance, obesity 
poses an independent risk factor for impaired insulin action.8 This presents an additional 
challenge to controlling postprandial blood glucose levels in children with T1DM, and 
thus, results in poor glycemic control. This is despite the clinical advances that have 
provided multiple interventions such as RAIAs and the continuous glucose monitoring 
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system. This study will provide important clinical information about the benefit of insulin 
injection site massage in improving RAIA absorption and action to match that of the 
physiologic insulin response. If demonstrated to be effective, insulin injection site 
massage combined with the already available approaches can potentially mitigate the risk 
factors that lead to late-stage progression of microvascular and macrovascular 
complications in this already high-risk population.  
 A development of such an intervention is not only imperative from a clinical 
aspect, but also from a public health standpoint. According to the American Diabetes 
Association, the estimated national medical cost associated with diabetes in 2012 was 
$176 billion. Out of this, 17% comes from the cost of antidiabetic agents and diabetes 
supplies.9 This high economic cost of diabetes has increased hand in hand with the 
increasing prevalence of diabetes10. Therefore, any non-costly and easily accessible 
intervention that will improve glycemic control and reduce the short and long-term 
complications of diabetes will be essential to alleviate the extensive economic burden of 
disease management. Ideally, this study will provide promising results that will 
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APPENDIX A: HIC INOFORMED CONSENT FORM  
 
PARENTAL CONSENT FOR CHILD/ADOLESCENT PARTICIPATION IN A 
RESEARCH PROJECT 
YALE UNIVERSITY SCHOOL OF MEDICINE - 
YALE NEW HAVEN HOSPITAL – SAINT RAPHEL CAMPUS  
 
Study Title: INJECTION SITE MASSAGE TO IMPROVE THE PHARMACOKINETICS 
OF ASPART IN OBESE ADOLESCENTS WITH DIABETES 
Principal Investigator: Hiwot K. Girma, PA-SII; Eda Cengiz, MD, MHS, FAAP 
Funding Source: Yale University School of Medicine, Department of Endocrinology 
Invitation to Participate and Description of Project 
 
 We are inviting your child to participate in a research study designed to look at the 
efficacy of injection site massage to accelerate the absorption and action of insulin. Your 
child has been asked to participate because he/she has type I diabetes for ≥ 1 year and has 
been identified by his/her endocrinologist as a good fit for this study based on the study 
inclusion criteria.  
 
 In order to decide whether or not you wish your child to be part of this research 
study you should know enough about its risks and benefits to make an informed decision. 
This permission form gives you detailed information about the research study, which a 
member of the research team will discuss with you. This discussion should go over all 
aspects of this research: its purpose, the procedures that will be performed, any risks of the 
procedures, and possible benefits. Once you understand the study, you will be asked if you 
wish your child to participate; if so, you will be asked to sign this form. 
 
Description of procedures 
 
 If you agree for your child to participate in this study, you will be asked to provide 
demographic and medical information about your child such as their age, gender, ethnicity, 
weight, past medical history, duration of diabetes, daily insulin dose, and previous insulin 
therapy. Your child will also be required to give 20ml of blood to assess the baseline 
HbA1c. This information will provide us with the details we need to determine if your child 
is eligible to enroll in the study. All information provided will be completely confidential. 
 
 Following this initial assessment, if your child is eligible for the study and you wish 
for him/her to participate, he/she will be enrolled into the study. The study will be 
performed in two separate days that are at least 1 week apart for boys and 4 weeks apart 
for girls. A computer program will be used to randomly assign participants to receive either 
the intervention or control treatment in different orderings for the two test days. Once your 
child is randomly assigned to the interventions, a member of our investigation team will sit 
down with you to give you details entailing each test day and procedures. 
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 On one of the test days, your child will receive an injection of Aspart, which is the 
standard of care for diabetes management, on the abdomen. If you are not familiar with 
this drug, it is an insulin therapy that belongs to the class of drugs that are commonly known 
as short or rapid-acting inulin analogs. Its other name is NovoLog and it is in the same 
class as Lispro (Humalog) and Glulisine (Apidra). It is approved by the Food and Drug 
Administration (FDA) for glucose control in patients with type I diabetes. On the other test 
day, your child will receive an injection of this same insulin followed by a 3 minute 
standardized injection site massage. The 3min massage is the intervention that is being 
investigated.  
 
 On the days of the study, each participant will be admitted to the Yale Hospital 
Research Unit for a 24 hours period. Your child will be admitted the afternoon prior to the 
study day after abstaining from caffeine, alcohol and strenuous exercise for at least 48hrs. 
Before the beginning of the study, all participants will undergo a thorough medical 
interview and physical examination by the principal investigator or other physician 
assistants who will be co-investigators on the study. Following this, the participants will 
be asked to lie flat on their back on a comfortable bed that we will provide for the length 
of the study. Two intravenous (IV) lines will be placed in your child’s arms, one for blood 
sampling and the other for the purpose of glucose infusion during the study. An insulin 
infusion set will also be inserted on the participant’s abdomen on the opposite side of the 
belly from where Aspart will be injected the next day. 
 
 Throughout the night before the study day, we will monitor your child’s blood 
glucose by sampling blood every hour. Based on his/her glucose level we will adjust the 
inulin that we will be infusing through the set that is placed on your child’s abdomen. Our 
goal is to achieve a good glucose level in preparation for the main procedure the next day. 
Participants will fast overnight and continue until the end of the procedure the next day. 
 
Insulin Action Study Procedure  
 On the morning of the study, based on your child’s random assignment he/she will 
receive a subcutaneous injection of Aspart at a previously marked abdominal injection site 
with or without a 3-min massage. After this, we will continually monitor your child’s blood 
glucose by sampling blood every 5 minutes from the IV line that was inserted the day 
before. Blood insulin levels will also be collected every 10min for the first 90min of the 
study and every 30min for the remainder of the study period. The total study period will be 
5 hours on each test day. 
 
Risks and Inconveniences 
 
Participants in this study may experience hypoglycemia, hypersensitivity reactions, 
local injection site reactions, lipodystrophy, rash and itching associated with the use of 
Aspart. However, the risk of your child experiencing these adverse effects is very rare, and 
we will minimize the possibility by the careful administration of Aspart and appropriate 
monitoring post-administration. Your child will be in the hands of very experienced Yale 
University investigators, PAs and nurses. 
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There are no known risks or side effects associated with the 3-minute local skin 
massage. Trained personnel will perform this intervention and we will be monitoring the 
massage site for any adverse reactions during and after the procedure.  
 
Even though very rare, you should also be aware of the risks associated with IV 
line placements and blood draws that will take place during the study. Trained clinical staff 
will perform blood draws for the initial assessment of HbA1c levels and also place the IV 
lines on the day of your child’s admission. General discomfort, excessive bleeding, feeling 
of lightheadedness, bruising from a small amount of bleeding under the skin, and minor 
infections are the possible, but rare side effects associated with these two procedures. The 
discomfort is transient and our trained clinicians will do their best to make your child 
comfortable. Excessive bleeding and lightheadedness are uncommon, but are easily 
treatable if necessary. A bruise will also go away once the IV line is removed, which we 
will do immediately if one is detected. Infections can also be treated, but our team will use 




Your child’s participation in this study will provide very critical information 
regarding the potential benefit of an injection site massage on the improvement of insulin 
absorption and action. Better insulin absorption and action will improve obese and 
overweight adolescents’ post-meal blood glucose values, which will have long-term 
clinical benefits. Additionally, if proven to positively affect insulin properties, your child’s 
participation in this study might in the future provide a cost-effective, and non-invasive 
intervention such as massage. 
 
In Case of Injury 
 
If your child is injured as a result of his/her participation in this study, treatment 
will be provided. You or your insurance provider will be expected to pay for the cost of 
this treatment. No additional financial compensation for injury or lost wages is available.  
 




All materials and procedures to be used in this study will come at no cost to you, 
your child or healthcare insurer. Your child will be offered a meal after the end of the 
procedure and can utilize the research unit’s facilities for personal hygiene needs. 
Otherwise, your child will not be offered any financial compensation for participating in 
the study.  
Confidentiality 
 
 Any identifiable information that is obtained in connection with this study will 
remain confidential and will be disclosed only with your permission or as required by U.S. 
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or State law. Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases. All identifying patient 
information obtained during the recruitment and study will remain confidential in 
accordance with Health Insurance Portability and Accountability Act (HIPAA) guidelines. 
Data entry and analysis by our team will be performed on encrypted computers that will 
only be accessible by a special password. This will remain confidential after the completion 
and publication of our work.  
 
 When the results of the research are published or discussed in conferences, no 
information will be included that would reveal your child’s identity unless your specific 
consent for this activity is obtained.   
 
 Representatives from the Yale Human Research Protection Program, the Yale 
Human Investigation Committee (the committee that reviews, approves, and monitors 
research on human subjects) may inspect study records during internal auditing procedures.  
However, these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
 
 Your child’s participation in this study is voluntary. You are free to choose not to 
have your child take part in this study. Refusing to participate will not involve any penalty 
or benefits to which your child is otherwise entitled, such as health care outside the study, 
the payment for your child’s health care, and health care benefits. However, you will not 
be able to enroll in this study and will not receive study procedures as a study participant 
if you do not allow use of your information as part of this study.  
 
 If your child does become a subject, you are free to stop and withdraw from this 
study at any time during its course. You can alert any of the investigators who will be in 
the study room that you no longer want your child to take part.   
 
 The researchers may withdraw your child from participating in the research if 
necessary. You may be withdrawn for reasons relating to your health status, progression of 
underlying disease or treatment, or non-adherence to the study protocol.  
 
 If you choose for your child to not participate or if you withdraw it will not harm 
your relationship with your child’s doctors at Yale Pediatrics Diabetes Clinic or with Yale 
New Haven Hospital. Your child will continue to receive a standard of care therapy without 




 We have used some technical terms in this form. Please feel free to ask about 
anything you don't understand and to consider this research and the consent form carefully 
– as long as you feel is necessary – before you make a decision. If you have any questions 
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I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of my child’s involvement 
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and possible hazards and inconveniences have been explained to my satisfaction.  My 





      










Signature of Principal Investigator  Date 
 
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator, contact information can be provided by your 
research associate. If, after you have signed this form you have any questions about your 
privacy rights, please contact the Yale Privacy Officer at 203-432-5919.If you would like 
to talk with someone other than the researchers to discuss problems, concerns, and 
questions you may have concerning this research, or to discuss your rights as a research 
subject, you may contact the Yale Human Investigation Committee at (203) 785-4688. 
 
 
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX 
HAS BEEN COMPLETED BY THE HIC OFFICE 
 
 







Appendix B: HIC Informed Child/Adolescent Assent Form  
 
CHILD/ADOLESCENT ASSENT FOR CHILD/ADOLESCENT 
PARTICIPATION IN A RESEARCH PROJECT 
YALE UNIVERSITY SCHOOL OF MEDICINE - 
YALE NEW HAVEN HOSPITAL – SAINT RAPHEL CAMPUS  
 
Title: INJECTION SITE MASSAGE TO IMPROVE THE PHARMACOKINETICS OF 
ASPART IN OBESE ADOLESCENTS WITH DIABETES 
 
Why am I here? 
 
 We are asking you to take part in a research study because we are trying to learn 
more about how to make the insulin injections that type I diabetes children take get 
absorbed faster and work quicker. We plan to do this by massaging your insulin injection 
site for 3 minutes after we inject your insulin on your belly. We are inviting you to be in 
the study because you have type I diabetes and already use an insulin injection.  
 
What will happen to me? 
 
 You will come into the hospital the afternoon before we do the study and stay 
overnight. We will ask you not to eat starting from when you come into the hospital until 
we finish the study the next day. We will have a comfortable bed for you to lie on when 
we do the test. Once you are comfortable, an experienced nurse will place an intravenous 
(IV) line on both of your arms. An IV line is a straw-like plastic that we put in your arm 
using a small needle to help us get some of your blood or inject medication. Another similar 
tube will also be inserted on your belly so we can use it to inject insulin to control you 
blood sugar levels until we start the study.  
 
 On the morning of the study, you will get an injection of insulin on your belly using 
a pen that will look very similar to what you have been using at home. Depending on what 
you were assigned to receive by our computer for that day, you will either get a 3 minute 
massage following the insulin injection or no massage. If you don’t get a massage that first 
test day, you will get it on the next test day you come into the hospital. After this, we will 
start drawing a small amount of blood from the IV lines that we had placed the night before 
every 5-10 minutes. The test day should take 5 hours and you will be offered a lunch when 
we are done with the study.  
 
Will the study hurt? 
 
 The initial IV placement in your arms might hurt a small amount, but the nurses, 






Will the study help me? 
 
 The study will not immediately help you at the time of the test. However, our 
goal, if the massage gives us good results, is that it will in the future help make your and 
other children’s blood sugar levels more controlled. 
 
What if I have any questions? 
  
 You can ask any questions that you have about the study. If you have a question 
later that you didn’t think of now, you can call me (917 638 8273) or ask me next time.  
 
Do my parents know about this? 
 
This study was explained to your parents and they agreed that you could be in it.  
You can talk this over with them before you decide. 
 
Do I have to be in the study? 
 
 You do not have to be in the study. No one will be upset if you don’t want to do 
this. If you don’t want to be in this study, you just have to tell us. You can say yes now and 



























Agreement to be in the Study:  
Writing your name on this page means that that you agree to be in the study, and know 
what will happen to you. If you decide to quit the study all you have to do is tell the 




_________________________________________                  ___________________ 
Signature of Child       Date 
 
_________________________________________                  ___________________ 




THIS FORM IS NOT VALID UNLESS THE FOLLOWING 
BOX HAS BEEN COMPLETED IN THE HIC OFFICE 
 
 
THIS FORM IS VALID ONLY THROUGH: 
____________________________________. 
 









Appendix C: Sample Size Calculation  
 
Using a statistical program (Power and Precision Version 4 Software), sample size was 
calculated using the values listed below: 
Effect Size: 33min 
Standard Deviation (SD): 41 
α (two-tailed) = 0.05 
β = 1 – 0.912 = 0.088 
 
Sample size required to compare means of continuous variables using a Paired t-test 
analysis and considering alpha and beta errors: 19 pairs  
Total participants/pairs required = 19  
+ a conservative 20% dropout/data loss rate = 23 pairs. 
 
Attrition rate was calculated from another euglycemic clamp study (Cengiz, 2013) using 
the formula: 
 
 Attrition rate =      Average number of subjects lost          ×   100 
      Average Number of subjects enrolled  
 












Appendix D: Sample Letter of recruitment to Clinicians at YPDC 
(Date) 
Dear (Name of Clinician),  
 We would like to let you know about a research study that the Yale Pediatric 
Endocrinology Department in coordination with Yale New Haven Hospital is planning to 
conduct within the next two years. We hope this letter followed by our planned 
information meeting next month will give you enough information to interest you in the 
study. We ask you to consider referring your patients for possible participation. 
 
The title of the study is:  
 
INJECTION SITE MASSAGE TO IMPROVE THE PHARMACOKINETICS OF 
ASPART IN OBESE ADOLESCENTS WITH DIABETES 
 
 The study we are conducting is a single-blinded, randomized controlled crossover 
trial to assess the efficacy of injection site massage in improving the pharmacokinetics 
and pharmacodynamics of aspart in overweight and obese adolescents with type I 
diabetes mellitus (T1DM).  
 There is an increasing incidence of obesity at the time of T1DM diagnosis in 
children, and the majority of children with T1DM have poor glycemic control. Obesity 
being an independent risk factor for impaired insulin action; it presents an additional 
challenge to controlling postprandial blood glucose with the use of pre-meal rapid-acting 
insulin analogs. Postprandial blood glucose excursions are known to have a strong 
correlation with the vascular morbidities associated with T1DM both directly and 
indirectly by affecting overall glycemic control. Therefore, an intervention that improves 
insulin action, to mitigate this post-meal glucose variability will be of critical value. We 
suspect that massage will have a beneficial role in accelerating subcutaneously 
administered insulin absorption and action to moderate the PPG levels that are elevated 
and prolonged in overweight and obese adolescents. Therefore, we wish to study the 
hypothesis that a standardized abdominal skin massage at the site of subcutaneous (SC) 
aspart injection will significantly increase in the rate of insulin absorption and action.  
   
Patients that meet the following criteria may be eligible for the study: 
 
Inclusion Criteria: 
• A clinical diagnosis of T1DM for ≥ 1 year.  
• On insulin therapy for at least 3 months 
• Age between 12 and 18 years old 
• BMI percentile that is ≥ 85% and < 99%  
• Hemoglobin A1c (HbA1c) < 10.0%  
• Non-smoker 
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• Able to abstain from alcohol, coffee and strenuous physical 
exercise at least 48hrs prior to study date 
• The ability to comprehend both written and spoken English 
 
Exclusion Criteria:  
 
• Any other Chronic Disease besides T1D 
• On any medication that might interfere with the absorption of 
insulin or blood glucose metabolism. 
• Pregnancy or breast-feeding 
• Any medical or psychosocial condition that might compromise the 
adolescent’s or parent’s ability to make an informed consent 
• Any skin diseases that might affect skin blood flow 
• HbA1c > 10% to eliminate the effect of poorly controlled diabetes 
 
 We invite you to a participate in a meeting at Yale Pediatric Diabetic Clinic on 
January __, 2015 at __PM to provide you with further details in regards to this study and 
recruitment process. We hope you can make it, but please feel free to contact us 
beforehand or after the meeting if you are not able to attend. You can reach as at (917) 
638 8273 or hiwot.girma@yale.edu 
 
We look forward to speaking with you and hope you are interested in working with us.  
 









Hiwot Ketema Girma, PA-SII        Dr. Eda Cengiz, MD, MHS, FAAP 
Yale Physician Associate Program   Assistant Professor of Pediatrics 
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